JP2011130770A5 - - Google Patents

Download PDF

Info

Publication number
JP2011130770A5
JP2011130770A5 JP2011012411A JP2011012411A JP2011130770A5 JP 2011130770 A5 JP2011130770 A5 JP 2011130770A5 JP 2011012411 A JP2011012411 A JP 2011012411A JP 2011012411 A JP2011012411 A JP 2011012411A JP 2011130770 A5 JP2011130770 A5 JP 2011130770A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
sarcoma
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011012411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011130770A (ja
JP5372973B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011130770A publication Critical patent/JP2011130770A/ja
Publication of JP2011130770A5 publication Critical patent/JP2011130770A5/ja
Application granted granted Critical
Publication of JP5372973B2 publication Critical patent/JP5372973B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011012411A 2002-06-19 2011-01-24 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー Expired - Lifetime JP5372973B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39020302P 2002-06-19 2002-06-19
US60/390,203 2002-06-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010000787A Division JP2010110329A (ja) 2002-06-19 2010-01-05 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー

Publications (3)

Publication Number Publication Date
JP2011130770A JP2011130770A (ja) 2011-07-07
JP2011130770A5 true JP2011130770A5 (enExample) 2012-05-10
JP5372973B2 JP5372973B2 (ja) 2013-12-18

Family

ID=30000526

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004516175A Expired - Lifetime JP4488512B2 (ja) 2002-06-19 2003-06-19 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
JP2010000787A Pending JP2010110329A (ja) 2002-06-19 2010-01-05 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
JP2011012411A Expired - Lifetime JP5372973B2 (ja) 2002-06-19 2011-01-24 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004516175A Expired - Lifetime JP4488512B2 (ja) 2002-06-19 2003-06-19 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
JP2010000787A Pending JP2010110329A (ja) 2002-06-19 2010-01-05 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー

Country Status (12)

Country Link
US (3) US7527969B2 (enExample)
EP (2) EP2277917A3 (enExample)
JP (3) JP4488512B2 (enExample)
AT (1) ATE488530T1 (enExample)
AU (1) AU2003243749B2 (enExample)
CA (1) CA2490399C (enExample)
DE (1) DE60335022D1 (enExample)
DK (1) DK1565489T3 (enExample)
ES (1) ES2356444T3 (enExample)
MX (1) MXPA04012664A (enExample)
PT (1) PT1565489E (enExample)
WO (1) WO2004001381A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE488530T1 (de) 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
EP1846032A4 (en) * 2005-01-31 2009-01-28 Raven Biotechnologies Inc LUCA2 AND THEREO BINDING ANTIBODIES
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド Ａｄａｍ−９モジュレータ
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP2094307A4 (en) * 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
AU2007317753B2 (en) * 2006-11-09 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
US20140315975A1 (en) 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG11201606714TA (en) 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
JP6602034B2 (ja) 2014-04-02 2019-11-06 日東電工株式会社 標的化分子およびその使用
CA2943733C (en) 2014-04-07 2022-03-01 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
UA128469C2 (uk) * 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
RS61828B1 (sr) * 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3638306A4 (en) * 2017-06-15 2020-07-01 Development Center for Biotechnology ANTIBODY DRUG CONJUGATES CONTAINING ANTI-GLOBO H ANTIBODIES AND USES THEREOF
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
EP4373505A1 (en) 2021-07-19 2024-05-29 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
US20250152643A1 (en) 2022-02-17 2025-05-15 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6001359A (en) * 1993-06-29 1999-12-14 Eli Lilly And Company Diagnosis of colon carcinoma using monoclonal antibodies to human influx peptide transporter
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2000068266A1 (en) 1999-05-11 2000-11-16 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
ES2539411T3 (es) * 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
JP2003512819A (ja) 1999-09-03 2003-04-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6987024B1 (en) 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1892251A3 (en) 2000-06-06 2008-12-31 Brystol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2002022683A1 (fr) 2000-09-12 2002-03-21 Kirin Beer Kabushiki Kaisha Nouvelle membrane a paroi cellulaire dendritique et son utilisation
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
WO2002032375A2 (en) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US20030039999A1 (en) 2001-05-25 2003-02-27 Amgen, Inc. B7 related protein-2 molecules and uses thereof
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1423402A4 (en) 2001-08-02 2006-07-05 Lilly Co Eli NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE
CA2475356A1 (en) 2002-02-12 2003-08-21 Raven Biotechnologies, Inc. Human fetal bladder-derived epithelial cells
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE488530T1 (de) * 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EP1534331B1 (en) 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers

Similar Documents

Publication Publication Date Title
JP2010110329A5 (enExample)
JP7259104B2 (ja) 抗ｔｒｏｐ２抗体－薬物コンジュゲート
CN111699197B (zh) 结合cd137的单结构域抗体
CN110913908B (zh) 靶向msln的三特异性蛋白质及使用方法
KR101901558B1 (ko) 항체-약물 콘주게이트
JP2010508847A5 (enExample)
JP2010533498A5 (enExample)
WO2015184941A1 (zh) 一种cd7纳米抗体、其编码序列及应用
JP2012502938A5 (enExample)
JP2005532050A5 (enExample)
CN113853388B (zh) 抗-egfrviii抗体及其抗原结合片段
TWI865753B (zh) 雙特異性抗體及其製造方法
CA2925915A1 (en) Anti-epcam antibodies and methods of use
WO2023066389A1 (zh) 靶向pd-1的双特异性抗体、及其制备和应用
CA3139827A1 (en) Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
JP2008526256A5 (enExample)
AU2020200574B2 (en) Methods and products for preventing and/or treating metastatic cancer
TW202104259A (zh) 癌治療用醫藥
CN118638225B (zh) 抗mic a/b的抗体及用途